The Shuman Law Firm Investigates DaVita, Inc.

BOULDER, Colo.--(BUSINESS WIRE)--The Shuman Law Firm today announced that it is investigating potential claims against certain officers and directors of directors of DaVita, Inc. (“DaVita” or the “Company”) (NYSE: DVA). DaVita provides kidney dialysis and administrative services, including related laboratory services for medical facilities across the United States. DaVita’s dialysis and related laboratory services business accounts for approximately 93% of the Company’s consolidated net operating revenues.

DaVita is the subject of two qui tam lawsuits which allege that DaVita executives have, for many years, systemically overprescribed patients their medications related to kidney dialysis in order to receive the maximum reimbursement from the federal government. These actions have purportedly cost taxpayers millions of dollars in illegal and unjustified payments to DaVita. DaVita is also currently being investigated by multiple U.S. Attorneys, the U.S. Department of Justice and the U.S. Department of Health and Human Services regarding these claims.

If you currently own DaVita common stock and are interested in discussing your rights as a shareholder, or have information relating to this investigation, please contact Kip B. Shuman or Rusty E. Glenn toll-free at [phone] or email Mr. Shuman at [e-mail] or email Mr. Glenn at [e-mail].

The Shuman Law Firm represents investors throughout the nation, concentrating its practice in securities class actions and shareholder derivative actions.